+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of neoadjuvant carboplatin combined with mirvetuximab soravtansine in adult women with advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that expresses folate receptor alpha FR. This phase 2, single-arm study focuses on patients with stage III or IV disease confirmed by specific diagnostic criteria. Mirvetuximab soravtansine is an investigational antibody drug conjugate designed to selectively target and kill cancer cells expressing FR. Participants receive intravenous infusions of mirvetuximab soravtansine together with carboplatin on day 1 of each 21-day cycle, for up to 6 to 9 cycles. Bevacizumab may also be given at the investigators discretion. The treatment is provided in a hospital or clinic setting. The total study duration, including treatment and follow-up, is approximately three years. During the study, participants attend regular visits for medical assessments, blood tests, and imaging scans to monitor their condition and treatment response. Researchers will evaluate the objective response to treatment by independent central review and investigator assessments, as well as safety through adverse event monitoring. Additional measures include progression-free survival, disease control, symptom changes, and surgery outcomes. The study aims to understand how well the treatment works and its safety profile over the course of the trial.

Age: 18Years +FEMALEPhase 2
73 locations
S

Actively Recruiting

Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.

Age: 18Years +All GendersPhase 2Phase 3
378 locations
R

Actively Recruiting

Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.

Age: 18Years +All GendersPhase 2
456 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
S

Actively Recruiting

Researchers are evaluating a treatment approach for patients with locally advanced cervical cancer that has spread to nearby tissues or lymph nodes. This phase III trial compares the addition of induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before the usual chemotherapy and radiation treatment combined with pembrolizumab, followed by pembrolizumab maintenance. The study aims to determine if adding induction therapy improves progression-free survival and overall survival, while assessing safety and biomarkers related to treatment response. Participants are randomly assigned to one of two groups. One group receives standard chemoradiation with cisplatin and pembrolizumab followed by pembrolizumab maintenance. The other group receives induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before starting chemoradiation and pembrolizumab maintenance. Chemoradiation includes weekly cisplatin, radiation therapy daily for 5 weeks, and brachytherapy treatments. Pembrolizumab is given intravenously at different intervals during the treatment and maintenance phases. Throughout the study, participants undergo various imaging scans such as PET, CT, chest x-ray, and MRI, along with blood sample collections to monitor their condition. Researchers evaluate outcomes including progression-free survival, overall survival, treatment side effects, treatment completion times, and biomarker levels. After completing treatments, participants are followed up every 3 months for 2 years, then every 6 months for 3 more years to monitor long-term effects and disease status.

Age: 18Years +FEMALEPhase 3
346 locations
C

Actively Recruiting

Researchers are comparing two chemotherapy regimens, mFOLFIRINOX and mFOLFOX, both with or without the immunotherapy drug nivolumab, for treating patients with advanced, unresectable, or metastatic HER2-negative adenocarcinoma of the esophagus, gastroesophageal junction, or stomach. This phase III trial aims to see if mFOLFIRINOX with or without nivolumab improves overall survival compared to mFOLFOX with or without nivolumab. The study also evaluates treatment safety, response rates, and explores biomarkers like PD-L1 combined positive score and cell-free DNA. Participants randomized to one of two groups will receive intravenous chemotherapy every 14 days in cycles up to 12 times. One group receives fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan, with nivolumab given as clinically indicated. The other group receives fluorouracil, leucovorin calcium, and oxaliplatin, also with nivolumab as needed. Throughout the study, patients undergo MRI and CT scans and may have blood samples collected. Nivolumab administration depends on clinical need. During the trial, participants will have regular imaging to monitor tumor status and blood tests to track biomarkers. Patient-reported outcomes on treatment side effects are collected at baseline and during cycles. After treatment, participants are followed every six months for up to three years or until tumor progression or withdrawal. The main outcome measured is overall survival over two years, with additional assessments of progression-free survival, response duration, and safety up to three years.

Age: 18Years +All GendersPhase 3
802 locations
C

Actively Recruiting

Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.

Age: 18Years +All GendersPhase 3
846 locations
E

Actively Recruiting

Researchers are studying pressurized intraperitoneal aerosol chemotherapy PIPAC to evaluate its safety and effects in patients with peritoneal carcinomatosis caused by ovarian, uterine, appendiceal, colorectal, or gastric cancers. This phase I trial aims to identify the maximum tolerated dose of PIPAC and assess safety across different patient groups, including those with advanced cancer spread to the abdominal lining. The study also explores response rates, surgical outcomes, progression-free survival, and patient quality of life. Participants are assigned to one of several groups based on their cancer type and prior treatments. Treatments involve PIPAC delivering chemotherapy drugs such as doxorubicin, cisplatin, oxaliplatin, mitomycin, and others directly into the abdomen through a minimally invasive laparoscopic procedure. Some groups receive additional intravenous chemotherapy drugs like leucovorin, fluorouracil, and irinotecan. Treatment cycles repeat every 4 to 6 weeks for up to three cycles if no disease progression or unacceptable side effects occur. During the study, participants undergo biopsies and imaging scans to evaluate tumor response using criteria like RECIST and peritoneal regression scores. Researchers also track surgical complications, technical success of PIPAC, and functional status through step monitoring devices. Quality-of-life questionnaires and symptom inventories are completed at regular intervals. After treatment, patients are followed every 12 weeks for up to three years to monitor outcomes and safety.

Age: 18Years +All GendersPhase 1
3 locations

1-10 of 19

1